Nolan Townsend, Lexeo Therapeutics CEO
October 30, 2024 03:29 PM EDT
R&D

Lex­eo shares ear­ly da­ta on Alzheimer’s gene ther­a­py 

Lei Lei Wu

News Reporter

Lex­eo Ther­a­peu­tics shared bio­mark­er da­ta from 15 pa­tients in a Phase 1/2 study of its gene ther­a­py for Alzheimer’s dis­ease. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Mi­crosoft-backed Enve­da rais­es $130M for drugs in I&I, obe­si­ty and oth­er ar­eas

Halozyme with­draws Evotec ac­qui­si­tion pro­pos­al af­ter biotech is 'un­will­ing to en­gage'

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times